# Aclaris Therapeutics, Inc.: financial statements, quarterly

ACRS · Nasdaq · CIK 1557746 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/acrs.md) · [Financials](/companies/acrs/financials.md) · [Filings](/companies/acrs/filings.md) · [Insiders](/companies/acrs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/acrs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9.3](/filings/0001558370-24-014646.md) | [17.6 d](/filings/0001558370-25-001819.md) | [2.4](/filings/0001558370-25-006993.md) | [2.8](/filings/0001558370-25-010789.md) | [4.3](/filings/0001104659-25-107788.md) | [9.2 d](/filings/0001104659-26-020540.md) | [1.5](/filings/0001104659-26-057202.md) | [1.8](/filings/0001104659-26-092065.md) | [3.3](/filings/0001104659-25-107788.md) | [1.3 d](/filings/0001104659-26-020540.md) | [2.0](/filings/0001104659-26-057202.md) | [1.6](/filings/0001104659-26-092065.md) |
| Cost of revenue | $m | [0.8](/filings/0001558370-24-014646.md) | [0.7 d](/filings/0001558370-25-001819.md) | [0.8](/filings/0001558370-25-006993.md) | [0.6](/filings/0001558370-25-010789.md) | [0.7](/filings/0001104659-25-107788.md) | [0.7 d](/filings/0001104659-26-020540.md) | [0.5](/filings/0001104659-26-057202.md) | [0.5](/filings/0001104659-26-092065.md) | [0.5](/filings/0001104659-25-107788.md) | [0.5 d](/filings/0001104659-26-020540.md) | [0.4](/filings/0001104659-26-057202.md) | [0.2](/filings/0001104659-26-092065.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [23.9](/filings/0001558370-24-014646.md) | [26.6 d](/filings/0001558370-25-001819.md) | [9.8](/filings/0001558370-25-006993.md) | [8.8](/filings/0001558370-25-010789.md) | [6.0](/filings/0001104659-25-107788.md) | [9.0 d](/filings/0001104659-26-020540.md) | [11.6](/filings/0001104659-26-057202.md) | [11.4](/filings/0001104659-26-092065.md) | [13.0](/filings/0001104659-25-107788.md) | [16.6 d](/filings/0001104659-26-020540.md) | [15.7](/filings/0001104659-26-057202.md) | [18.1](/filings/0001104659-26-092065.md) |
| Operating income | $m | [(31.6)](/filings/0001558370-24-014646.md) | [(4.0) d](/filings/0001558370-25-001819.md) | [(18.9)](/filings/0001558370-25-006993.md) | [(12.9)](/filings/0001558370-25-010789.md) | [(10.5)](/filings/0001104659-25-107788.md) | [(99.7) d](/filings/0001104659-26-020540.md) | [(18.1)](/filings/0001104659-26-057202.md) | [(18.4)](/filings/0001104659-26-092065.md) | [(17.1)](/filings/0001104659-25-107788.md) | [(22.7) d](/filings/0001104659-26-020540.md) | [(22.2)](/filings/0001104659-26-057202.md) | [(24.2)](/filings/0001104659-26-092065.md) |
| Net income | $m | [(29.3)](/filings/0001558370-24-014646.md) | [(1.5) d](/filings/0001558370-25-001819.md) | [(16.9)](/filings/0001104659-25-107788.md) | [(11.0)](/filings/0001104659-25-107788.md) | [(7.6)](/filings/0001104659-25-107788.md) | [(96.6) d](/filings/0001104659-26-020540.md) | [(15.1)](/filings/0001104659-26-092065.md) | [(15.4)](/filings/0001104659-26-092065.md) | [(14.6)](/filings/0001104659-25-107788.md) | [(19.8) d](/filings/0001104659-26-020540.md) | [(19.8)](/filings/0001104659-26-092065.md) | [(21.5)](/filings/0001104659-26-092065.md) |
| Diluted EPS | $ per share | [(0.41)](/filings/0001558370-24-014646.md) | not reported | [(0.24)](/filings/0001558370-25-006993.md) | [(0.15)](/filings/0001558370-25-010789.md) | [(0.11)](/filings/0001104659-25-107788.md) | not reported | [(0.12)](/filings/0001104659-26-057202.md) | [(0.13)](/filings/0001104659-26-092065.md) | [(0.12)](/filings/0001104659-25-107788.md) | not reported | [(0.15)](/filings/0001104659-26-057202.md) | [(0.15)](/filings/0001104659-26-092065.md) |
| Basic EPS | $ per share | [(0.41)](/filings/0001558370-24-014646.md) | not reported | [(0.24)](/filings/0001558370-25-006993.md) | [(0.15)](/filings/0001558370-25-010789.md) | [(0.11)](/filings/0001104659-25-107788.md) | not reported | [(0.12)](/filings/0001104659-26-057202.md) | [(0.13)](/filings/0001104659-26-092065.md) | [(0.12)](/filings/0001104659-25-107788.md) | not reported | [(0.15)](/filings/0001104659-26-057202.md) | [(0.15)](/filings/0001104659-26-092065.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [39.0](/filings/0001558370-23-017660.md) | [39.9](/filings/0001558370-25-001819.md) | [35.8](/filings/0001558370-24-007069.md) | [22.8](/filings/0001558370-24-011376.md) | [47.7](/filings/0001558370-24-014646.md) | [24.6](/filings/0001104659-26-020540.md) | [30.4](/filings/0001558370-25-006993.md) | [25.4](/filings/0001558370-25-010789.md) | [25.3](/filings/0001104659-25-107788.md) | [20.0](/filings/0001104659-26-092065.md) | [28.7](/filings/0001104659-26-057202.md) | [19.2](/filings/0001104659-26-092065.md) |
| Current assets | $m | [123](/filings/0001558370-23-017660.md) | [129](/filings/0001558370-25-001819.md) | [135](/filings/0001558370-24-007069.md) | [118](/filings/0001558370-24-011376.md) | [132](/filings/0001558370-24-014646.md) | [126](/filings/0001104659-26-020540.md) | [109](/filings/0001558370-25-006993.md) | [104](/filings/0001558370-25-010789.md) | [101](/filings/0001104659-25-107788.md) | [96.3](/filings/0001104659-26-092065.md) | [110](/filings/0001104659-26-057202.md) | [97.8](/filings/0001104659-26-092065.md) |
| Total assets | $m | [218](/filings/0001558370-23-017660.md) | [197](/filings/0001558370-25-001819.md) | [174](/filings/0001558370-24-007069.md) | [161](/filings/0001558370-24-011376.md) | [182](/filings/0001558370-24-014646.md) | [220](/filings/0001104659-26-020540.md) | [198](/filings/0001558370-25-006993.md) | [189](/filings/0001558370-25-010789.md) | [176](/filings/0001104659-25-107788.md) | [160](/filings/0001104659-26-092065.md) | [199](/filings/0001104659-26-057202.md) | [180](/filings/0001104659-26-092065.md) |
| Current liabilities | $m | [27.3](/filings/0001558370-23-017660.md) | [31.0](/filings/0001558370-25-001819.md) | [20.1](/filings/0001558370-24-007069.md) | [15.7](/filings/0001558370-24-011376.md) | [18.8](/filings/0001558370-24-014646.md) | [31.6](/filings/0001104659-26-020540.md) | [21.5](/filings/0001558370-25-006993.md) | [26.8](/filings/0001558370-25-010789.md) | [25.6](/filings/0001104659-25-107788.md) | [28.6](/filings/0001104659-26-092065.md) | [27.4](/filings/0001104659-26-057202.md) | [28.2](/filings/0001104659-26-092065.md) |
| Total liabilities | $m | [62.0](/filings/0001558370-23-017660.md) | [40.2](/filings/0001558370-25-001819.md) | [32.1](/filings/0001558370-24-007069.md) | [27.2](/filings/0001558370-24-011376.md) | [52.2](/filings/0001558370-24-014646.md) | [64.8](/filings/0001104659-26-020540.md) | [54.0](/filings/0001558370-25-006993.md) | [57.4](/filings/0001558370-25-010789.md) | [55.4](/filings/0001104659-25-107788.md) | [57.4](/filings/0001104659-26-092065.md) | [55.1](/filings/0001104659-26-057202.md) | [55.1](/filings/0001104659-26-092065.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [156](/filings/0001558370-24-014646.md) | [157](/filings/0001104659-26-020540.md) | [142](/filings/0001104659-25-107788.md) | [134](/filings/0001104659-25-107788.md) | [130](/filings/0001104659-25-107788.md) | [156](/filings/0001104659-26-092065.md) | [144](/filings/0001104659-26-092065.md) | [132](/filings/0001104659-26-092065.md) | [120](/filings/0001104659-25-107788.md) | [103](/filings/0001104659-26-092065.md) | [144](/filings/0001104659-26-092065.md) | [125](/filings/0001104659-26-092065.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(24.6) d](/filings/0001558370-24-014646.md) | [(6.8) d](/filings/0001558370-25-001819.md) | [(20.8)](/filings/0001558370-25-006993.md) | [(12.3) d](/filings/0001558370-25-010789.md) | [22.0 d](/filings/0001104659-25-107788.md) | [(8.9) d](/filings/0001104659-26-020540.md) | [(13.1)](/filings/0001104659-26-057202.md) | [(10.0) d](/filings/0001104659-26-092065.md) | [(10.9) d](/filings/0001104659-25-107788.md) | [(13.1) d](/filings/0001104659-26-020540.md) | [(18.1)](/filings/0001104659-26-057202.md) | [(19.8) d](/filings/0001104659-26-092065.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001558370-24-014646.md) | [0.4 d](/filings/0001558370-25-001819.md) | [0.1](/filings/0001558370-25-006993.md) | [(0.0) d](/filings/0001558370-25-010789.md) | [0.0 d](/filings/0001104659-25-107788.md) | [0.0 d](/filings/0001104659-26-020540.md) | [0.0](/filings/0001104659-26-057202.md) | [0.0 d](/filings/0001104659-26-092065.md) | [0.0 d](/filings/0001104659-25-107788.md) | [0.0 d](/filings/0001104659-26-020540.md) | [0.0](/filings/0001104659-26-057202.md) | [0.1 d](/filings/0001104659-26-092065.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [66.7](/filings/0001558370-23-017660.md) | [66.9](/filings/0001558370-24-007069.md) | [70.6](/filings/0001558370-24-011376.md) | [70.8](/filings/0001558370-24-014646.md) | [71.1](/filings/0001558370-25-006993.md) | [71.3](/filings/0001558370-25-010789.md) | [71.4](/filings/0001104659-25-107788.md) | [122](/filings/0001104659-26-057202.md) | [123](/filings/0001104659-26-092065.md) | [123](/filings/0001104659-25-107788.md) | [129](/filings/0001104659-26-057202.md) | [143](/filings/0001104659-26-092065.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 147,198,893 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001104659-26-092065.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.